Risk Evaluation for Trichloroe

Supplemental Information

Risk Calculator for Occupational

Table of Contents
Worksheet
Dashboard
RR
RR <PEL
Health Data
Dermal Exposure
Inhalation Exposure
Inhalation <PEL

PEER REVIEW DRAFT. DO NOT CITE O

 Risk Evaluation for Trichloroethylene

Supplemental Information File:

Risk Calculator for Occupational Exposures

Description
This tab calculates and displays inhalation MOE values by condition of use, type of worker, and type of respiratory protection (b
This tab displays the risk reduction/management options for inhalation and dermal routes (based on user selection in "Dashbo
Same tab as the RR tab above except the inhalation data has been limited to samples beneath the PEL for TCE.
This tab displays the establisheed dermal and inhalation risks for human toxicity endpoints and the associated MOE.
This tab contains the dermal exposure estimates for the selected condition of use (dose)
This tab contains the inhalation exposure estimates for all conditions of use (dose)
The same tab as Inhalation Exposure above except the inhalation data has been limited to samples beneath the PEL for TCE.

PEER REVIEW DRAFT. DO NOT CITE OR QUOTE

 Trichloroethylene Risk Calcula
Introduction:

The TCE Risk Calculator was generated to provide reviewers with snapshots of TCE risk based on various parameters. Be
“Dashboard” and “RR” tabs.

Dashboard:
This is the main overview tab that showcases the risk associated with a selected condition of use. The user can select fr
Condition of Use: choose the work activity (Occupational Exposure Scenario), such as Manufacturing or Cold
Data Type: choose Monitoring Data or Modeled Data
HEC Level: choose 50th or 99th percentile estimates of the human equivalent concentration (HEC)
Respirator Protection Factor: choose the level of respiratory protection (the calculator automatically shows
Glove Protection Factor: choose the level of dermal hand protection (the calculator automatically shows no
Worker Type: choose the worker type.
HED Level: choose 50th or 99th percentile estimates of the human equivalent dose (HED)

The calculator will automatically display the associated data, showing acute; chronic, non-cancer; and chronic, cancer e
selection, it will show up as blank. In situations where no results are shown, try adjusting the data type from modeled t

The calculator takes the exposure outputs and compares this data to the HEC and MOE (Margin of Exposure) of studied
study’s listed MOE is flagged red and represents risk.

Cancer risks are provided on a gradient to show risk of 1 in 10,000 up to 1 in 1,000,000.

RR:

The RR tab is very similar to the Dashboard tab but focuses on showing the risk across all levels of PPE. Inhalation expo
protection factors of 10 to 10,000. The same is done for dermal exposure risk, providing occluded, no gloves, and glove
Dashboard tab, except for the worker type.
Worker Type: choose the worker type - choose ONU or Worker
The “RR” tab has a similar layout to the “Dashboard” tab but is tweaked to allow for the information discussed above to
has been limited to datapoints beneath the PEL.

User Selection Box

Health Data:

This tab holds the lookup values for the health endpoints across acute; chronic, non-cancer; and chronic, cancer exposu
corresponding health endpoints displayed on the respective tabs.
Dermal Crosswalk:
This tab is a helper tab to the Dermal Exposure tab. This tab provides information on the bin, TCE concentration, occlus

Dermal Exposure:
This tab calculates the dermal exposures for the “Dashboard” and “RR” tabs based on the criteria selected in the respec
tab.
Inhalation Exposure:
This is a data table that was generated from all the inhalation data compiled from the various monitoring sources as we
was limited to data points beneath the PEL.
List Values:
This tab calculates the dermal exposures for the “Dashboard” and “RR” tabs based on the criteria selected in the respec
tab.
Exposure Factors:
This is a data table that was generated from all the inhalation data compiled from the various monitoring sources as we
“Inhalation Exposure” tab for reference by the calculator.
ne Risk Calculator User Guide

ed on various parameters. Below is an overview of the tabs, their functions, and how they each relate to the

of use. The user can select from the following selectors:

such as Manufacturing or Cold Cleaning

ncentration (HEC)
lculator automatically shows no respiratory protection alongside this selection).
ulator automatically shows no glove and occluded scenarios alongside this selection).

ose (HED)

cancer; and chronic, cancer exposures for inhalation and dermal scenarios. If data does not exist for a certain
the data type from modeled to monitoring data (or vice versa) as not all scenarios have both types available.

Margin of Exposure) of studied toxic endpoints compiled in the “Health Data” tab. Any exposure below the

User Selection Boxes Associated TCE

Exposures

Acute, Non-Cancer
risk to various health
endpoints.
 evels of PPE. Inhalation exposure risk is shown without a respirator, and with respirators of increasing
occluded, no gloves, and gloved scenarios side by side. The parameters are tied to the selections made in the

nformation discussed above to be clearly shown. The "RR <PEL" tab is the same as the "RR" tab except the data

User Selection Box

Gradations of PPE protection factors

displayed across health endpoints.

er; and chronic, cancer exposures. Both “Dashboard” and “RR” tabs lookup data from this table for the various

bin, TCE concentration, occlusion consideration, and fraction absorbed for each condition of use.

criteria selected in the respective tabs while looking up condition of use specific data from the dermal crosswalk

ous monitoring sources as well as inhalation exposure models. The "Inhalation <PEL" is similar, except this data
criteria selected in the respective tabs while looking up condition of use specific data from the dermal crosswalk

ous monitoring sources as well as inhalation exposure models. This data is then hard entered into the
 Condition of Use Inhalation Exposure
Data Type HEC Level
Select the Condition of Use (select) (select)
Monitoring
Manufacturing 99%
Data

8-hr and 12-hr TWA Exposures

Exposure Outputs
Full-Shift (Eight-Hour)
Acute Exposures
TWA Exposure
Category Exposure Level
CTCE, 8 or 12-hr TWA (ppm) ACTCE, 24-hr TWA (ppm)

Worker 3 1
High End
ONU
Worker 0 0
Central Tendency
ONU

Risk Estimation for Acute, Non-Cancer Inhalation Exposures

Benchmark MOE
Health Effect, Endpoint and Study HEC (ppm) Exposure Level (= Total UF)

Developmental Toxicity High End 10

Congenital heart malformations 0.0037
Johnson et al., 2003 Central Tendancy 10

Developmental Toxicity High End 100

Developmental neurotoxicity 3
Fredriksson et al., 1993 Central Tendancy 100

Developmental Toxicity High End 10

Pre- and postnatal mortality 23
Narotsky et al., 1995 Central Tendancy 10

Immunotoxicity High End 30

Response to infection 1.74
Selgrade et al., 2010 Central Tendancy 30

Risk Estimation for Chronic, Non-Cancer Inhalation Exposures

Benchmark MOE
Health Effect, Endpoint and Study HEC (ppm) Exposure Level (= Total UF)
 Benchmark MOE
Health Effect, Endpoint and Study HEC (ppm) Exposure Level (= Total UF)

Liver High End 10

Increased liver weight, cytotoxicity, and
hypertrophy 9.1
Kjellstrand et al. 1983 Central Tendancy 10

Kidney High End 10

Kidney pathology 0.025
Maltoni, 1986 (Oral) Central Tendancy 10

Neurotoxicity High End 300

CNS depression 4.8
Arito et al., 1994 Central Tendancy 300

Neurotoxicity High End 10

Trigeminal nerve effects 5.3
Ruijten et al., 1991 Central Tendancy 10

Immunotoxicity High End 30

Autoimmunity 0.033
Keil et al., 2009 Central Tendancy 30

Immunotoxicity High End 100

Immunosuppression 1.7
Sanders et al., 1982 Central Tendancy 100

Reproductive Toxicity High End 30

Male reproductive toxicity 0.5
Chia et al. 1996 Central Tendancy 30

Reproductive Toxicity High End 100

Female reproductive toxicity 37
Narotsky et al., 1995 Central Tendancy 100

Developmental Toxicity High End 10

Congenital defects 0.0037
Johnson et al., 2003 Central Tendancy 10

Developmental Toxicity High End 300

Developmental neurotoxicity 3
Fredriksson et al., 1993 Central Tendancy 300

Developmental Toxicity High End 10

Pre- and postnatal mortality 23
Narotsky et al., 1995 Central Tendancy 10

Cancer Risks
Risk Estimate IUR (ppm-1) Exposure Level Benchmark

Cancer High End 10-4

Liver, Kidney, NHL 0.02
Charbotel et al., 2006 (adjusted)
Central Tendency 10-4

Inhalation Cancer Risk Estimates

1E-7 1E-6 1E-5 1E-4 1E-3 1E-2 1E-1 1E+0

 Inhalation Cancer Risk Estimates

1E-7 1E-6 1E-5 1E-4 1E-3 1E-2 1E-1 1E+0

1

Worker: 95th Percentile 0.1

0.01

Worker: 50th Percentile

0.001
Cancer R
0.0001Cancer R
ONU: 95th Percentile 1000

0.00001

ONU: 50th Percentile 0.000001

0.0000001

Excess Cancer Risk

Cancer Risk with APF

Inhalation Cancer Risk Estimates Cancer Risk of 1000
ONU: 50th Percentile 0.00E+00 0.00E+00
ONU: 95th Percentile 0.00E+00 0.00E+00
Worker: 50th Percentile 7.49E-04 7.49E-07
Worker: 95th Percentile 6.67E-03 6.67E-06
 Personal Protective Equipment (PPE)
Respirator Protection Glove Protection
Factor (Select) Factor (Select)

1000 5

Chronic, Non-Cancer
Chronic, Cancer Exposures
Exposures

ADCTCE, 24-hr TWA (ppm) LADCTCE, 24-hr TWA (ppm)

1 0.30

0 0.03

Acute Exposure Estimates Respirator Scenario: APF of 1000

Worker MOE ONU MOE Worker MOE ONU MOE

0.00 4.29

0.03 29.59

3.48 3477.32

23.99 23988.41

26.66 26659.42

183.91 183911.11

2.02 2016.84

13.91 13913.28

Chronic Exposure Estimates Respirator Scenario: APF of 1000

 Worker MOE ONU MOE Worker MOE ONU MOE

15.40 15399.87

106.24 106236.65

0.04 42.31

0.29 291.86

8.12 8123.01

56.04 56036.92

8.97 8969.16

61.87 61874.09

0.06 55.85

0.39 385.25

2.88 2876.90

19.85 19846.41

0.85 846.15

5.84 5837.18

62.61 62614.87

431.95 431951.22

0.01 6.26

0.04 43.20

5.08 5076.88

35.02 35023.07

38.92 38922.76

268.51 268510.22

Chronic Cancer Exposure Estimates Respirator Scenario: APF of 1000

Worker ONU Worker ONU

0.0067 0.0000 0.0000 0.0000

0.0007 0.0000 0.0000 0.0000

1E-1 1E+0
1E-1 1E+0
1

0.1

0.01

0.001
Cancer Risk
0.0001Cancer Risk with APF of
1000

0.00001

0.000001

0.0000001
 Dermal
Worker Type HED Level
(select) (select)

Average Adult Worker 99%

Dermal
Exposure Outputs
Acute Potential Dose
Acute Retained Dose
Rate
Category Exposure Level
APDRexp (mg/day) ARDTCE (mg/kg-day)

High End 184 2.3

Worker, No Gloves
Central Tendency 61 1
Worker with Gloves; High End 37 0
PF = 5 Central Tendency 12 0

Risk Estimation for Acute, Non-Cancer Dermal Exposures

Benchmark MOE
Health Effect, Endpoint and Study Acute HED (mg/kg) Exposure Level (= Total UF)

Developmental Toxicity High End 10

Congenital heart malformations 0.0052
Johnson et al., 2003 Central Tendancy 10

Developmental Toxicity High End 100

Developmental neurotoxicity 4.1
Fredriksson et al., 1993 Central Tendancy 100

Developmental Toxicity High End 10

Pre- and postnatal mortality 28
Narotsky et al., 1995 Central Tendancy 10

Immunotoxicity High End 30

Response to infection 2.74
Selgrade et al., 2010 Central Tendancy 30

Risk Estimation for Chronic, Non-Cancer Dermal Exposures

Benchmark MOE
Health Effect, Endpoint and Study HED (mg/kg) Exposure Level (= Total UF)
 Benchmark MOE
Health Effect, Endpoint and Study HED (mg/kg) Exposure Level (= Total UF)

Liver High End 10

Increased liver weight, cytotoxicity, and
hypertrophy 7.9
Kjellstrand et al. 1983 Central Tendancy 10

Kidney High End 10

Kidney pathology 0.015
Maltoni, 1986 (Oral) Central Tendancy 10

Neurotoxicity High End 300

CNS depression 6.5
Arito et al., 1994 Central Tendancy 300

Neurotoxicity High End 10

Trigeminal nerve effects 7.3
Ruijten et al., 1991 Central Tendancy 10

Immunotoxicity High End 30

Autoimmunity 0.048
Keil et al., 2009 Central Tendancy 30

Immunotoxicity High End 100

Immunosuppression 2.5
Sanders et al., 1982 Central Tendancy 100

Reproductive Toxicity High End 30

Male reproductive toxicity 0.73
Chia et al. 1996 Central Tendancy 30

Reproductive Toxicity High End 100

Female reproductive toxicity 44
Narotsky et al., 1995 Central Tendancy 100

Developmental Toxicity High End 10

Congenital defects 0.0052
Johnson et al., 2003 Central Tendancy 10

Developmental Toxicity High End 300

Developmental neurotoxicity 4.1
Fredriksson et al., 1993 Central Tendancy 300

Developmental Toxicity High End 10

Pre- and postnatal mortality 28
Narotsky et al., 1995 Central Tendancy 10

Cancer Risks
Risk Estimate OSP (mg/kg-1) Exposure Level Benchmark

Cancer High End 10-4

Liver, Kidney, NHL 0.05
Charbotel et al., 2006 (adjusted)
Central Tendency 10-4
 Dermal Cancer Risk Estimates

1E-7 1E-6 1E-5 1E-4 1E-3 1E-2 1E-1

Gloves: 5

No Gloves

0.0000001 0.000001 0.00001 0.0001 0.001 0.01 0.1 1

Excess Cancer Risk

Dermal Cancer Risk Estimates High End Central Tendency

No Gloves 3.76E-02 9.70E-03

Gloves: 5 7.51E-03 1.94E-03
 Chronic Retained Dose,
Chronic Retained Dose, Non-Cancer Cancer

CRDTCE (mg/kg-day) CRDTCE (mg/kg-day)

2 1
0.53 0.21
0.32 0.16
0.11 0.04

Acute Exposure Estimates Gloved Scenarios

Worker MOE, No Gloves Worker MOE with Gloves: 5

0.00 0.01

0.01 0.03

1.78 8.90

5.3 26.7

12.15 60.75

36.45 182.25

1.19 5.94

3.57 17.83

Chronic Exposure Estimates Gloved Scenarios

 Worker MOE, No Gloves Worker MOE with Gloves: 5

5.01 25.03

15.02 75.08

0.01 0.05

0.03 0.14

4.12 20.59

12.35 61.77

4.62 23.12

13.87 69.37

0.03 0.15

0.09 0.46

1.58 7.92

4.75 23.76

0.46 2.31

1.39 6.94

27.88 139.38

83.63 418.14

0.00 0.02

0.01 0.05

2.60 12.99

7.79 38.96

17.74 88.70

53.22 266.09

Chronic Cancer Exposure Estimates Gloved Scenarios

No Gloves Gloves: 5

0.0376 0.0075

0.0097 0.0019
 1E-2 1E-1 1E+0
1

0.1

0.01

0.001High End

Central Tendency
0.0001

0.00001

0.000001

0.0000001
01 0.1 1
 Key
= Risk. MOEacute or chronic < MOEbenchmark
Cancer Risk > Benchmark Cancer Risk Level

= No Risk. MOEacute or chronic ≥ MOEbenchmark

Cancer Risk ≤ Benchmark Cancer Risk Level

Risk Type Toxicity Endpoint Study

Congenital heart Johnson et al., 2003

malformations
Developmental Developmental Fredriksson et al.,
Toxicity neurotoxicity 1993
Acute, Non-
Cancer Pre- and postnatal Narotsky et al., 1995
mortality

Immunotoxicity Response to infection Selgrade et al., 2010

Increased liver weight,
Liver cytotoxicity, and Kjellstrand et al. 1983
hypertrophy
Kidney Kidney pathology Maltoni, 1986 (Oral)

CNS depression Arito et al., 1994

Neurotoxicity
Trigeminal nerve effects Ruijten et al., 1991

Autoimmunity Keil et al., 2009

Immunotoxicity
Chronic, Immunosuppression Sanders et al., 1982
Non-Cancer
Male reproductive toxicity Chia et al. 1996
Reproductive
Toxicity Female reproductive Narotsky et al., 1995
toxicity
Congenital defects Johnson et al., 2003

Developmental
Toxicity
 Congenital defects Johnson et al., 2003

Developmental Developmental Fredriksson et al.,

Toxicity neurotoxicity 1993
Pre- and postnatal Narotsky et al., 1995
mortality

Chronic, Charbotel et al., 2006

Cancer Kidney, liver, NHL
Cancer (adjusted)

1E-7

APF = 10,000

APF = 1,000

APF = 50

APF = 25

APF = 10

No Respirator

=
 Condition of Use Inhalation Exposure
Exposure Type
Select the Condition of Use Data Type HEC Level (select)

Manufacturing Monitoring Data 99% Worker

8-hr and 12-hr TWA Exposures

Exposure Outputs

Full-Shift (Eight-Hour) Chronic, Non-

Acute Exposures
TWA Exposure Cancer Exposures
Category Exposure Level
CTCE, 8 or 12-hr TWA (ppm) ACTCE, 24-hr TWA (ppm) ADCTCE, 24-hr TWA (ppm)

Worker 3 1 1
High End
ONU
Worker 0 0 0
Central Tendency
ONU

Risk Estimation for Inhalation Exposures

Benchmark MOE Exposure Es
HEC (ppm) Exposure Level (= Total UF) No Respirator APF = 10
High End 10 0.00 0.04
0.0037
Central Tendancy 10 0.03 0.30
High End 100 3.48 34.77
3
Central Tendancy 100 23.99 239.88
High End 10 26.66 266.59
23
Central Tendancy 10 183.91 1839.11
High End 30 2.02 20.17
1.74
Central Tendancy 30 13.91 139.13
High End 10 15.40 154.00
9.1
Central Tendancy 10 106.24 1062.37
High End 10 0.04 0.42
0.025
Central Tendancy 10 0.29 2.92
High End 300 8.12 81.23
4.8
Central Tendancy 300 56.04 560.37
High End 10 8.97 89.69
5.3
Central Tendancy 10 61.87 618.7
High End 30 0.06 0.56
0.033
Central Tendancy 30 0.39 3.85
High End 100 2.88 28.77
1.7
Central Tendancy 100 19.85 198.5
High End 30 0.85 8.46
0.5
Central Tendancy 30 5.84 58.4
High End 100 62.61 626.15
37
Central Tendancy 100 431.95 4,319.5
High End 10 0.01 0.06
0.0037
 0.0037
Central Tendancy 10 0.04 0.43
High End 300 5.08 50.77
3
Central Tendancy 300 35.02 350.2
High End 10 38.92 389.23
23
Central Tendancy 10 268.51 2685.10
High End 10-4 0.0067 6.7E-04
0.022
Central Tendency 10-4 0.0007 7.5E-05

Inhalation Cancer Risk Estimates

1E-7 1E-6 1E-5 1E-4 1E-3 1E-2 1E-1 1E+0
1
APF = 10,000
0.1
APF = 1,000
0.01

APF = 50 0.001 High

Centr
APF = 25 0.0001

0.00001
APF = 10
0.000001
No Respirator
0.0000001

Excess Cancer Risk

Inhalation Cancer Risk

High End Central Tendency
Estimates
No Respirator 6.67E-03 7.49E-04
APF = 10 6.67E-04 7.49E-05
APF = 25 2.67E-04 3.00E-05

APF = 50 1.33E-04 1.50E-05

APF = 1,000 6.67E-06 7.49E-07
APF = 10,000 6.67E-07 7.49E-08
 Dermal
Worker Type

Average Adult Worker

Dermal
Exposure Outputs

Chronic, Cancer
Exposures
Category
LADCTCE, 24-hr TWA
(ppm)
0
Worker, No Gloves
0 Worker with Gloves; PF =
5
Worker with Gloves; PF =
10
Worker with Gloves; PF =
20

Risk Estimation for Dermal Exposures

Exposure Estimates: Worker MOE
HED (mg/kg)
APF = 25 APF = 50 APF = 1,000 APF = 10,000
0.11 0.21 4.29 42.9
0.0052
0.74 1.48 29.59 295.9
86.9 173.9 3,477.3 34,773.2
4.1
599.71 1199.42 23988.41 239,884.1
666.5 1,333.0 26,659.4 266,594.2
28
4597.78 9195.56 183911.11 1,839,111.1
50.4 100.8 2,016.8 20,168.4
2.74
347.83 695.66 13913.28 139,132.8
385.0 770.0 15,399.9 153,998.7
7.9
2655.92 5311.83 106236.65 1,062,366.5
1.1 2.1 42.3 423.1
0.015
7.30 14.59 291.86 2,918.6
203.1 406.2 8,123.0 81,230.1
6.5
1400.92 2801.85 56036.92 560,369.2
224.2 448.5 8,969.2 89,691.6
7.3
1546.85 3093.70 61874.09 618,740.9
1.4 2.8 55.8 558.5
0.048
9.63 19.26 385.25 3,852.5
71.9 143.8 2,876.9 28,769.0
2.5
496.16 992.32 19846.41 198,464.1
21.2 42.3 846.1 8,461.5
0.73
145.93 291.86 5837.18 58,371.8
1,565.4 3,130.7 62,614.9 626,148.7
44
10798.78 21597.56 431951.22 4,319,512.2
0.16 0.31 6.26 62.6
0.0052
 0.0052
1.08 2.16 43.20 432.0
126.92 253.84 5076.88 50,768.8
4.1
875.58 1751.15 35023.07 350,230.7
973.1 1,946.1 38,922.8 389,227.6
28
6712.76 13425.51 268510.22 2,685,102.2
0.00 0.00 0.00 6.7E-07
0.0464
0.00 0.00 0.00 7.5E-08

E-1 1E+0 1E-7 1E-6 1

1
Protective Gloves
0.1 (Industrial uses, PF = 20)
0.01
Protective Gloves
0.001 High End (Commercial uses, PF = 10)
Central Tendency
0.0001
Protective Gloves (PF = 5)
0.00001

0.000001
No Gloves (PF = 1)
0.0000001

0.0000001 0.000001 0.000

Dermal Cancer Risk

Estimates
No Gloves (PF = 1)
Protective Gloves (PF = 5)
Protective Gloves
(Commercial uses, PF = 10)
Protective Gloves
(Industrial uses, PF = 20)
 Dermal
HED Level

99%

Chronic Chronic
Acute Potential Dose Acute Retained Retained Dose, Retained Dose,
Rate Dose
Exposure Level Non-Cancer Cancer
ARDTCE (mg/kg- CRDTCE (mg/kg- CRDTCE (mg/kg-
APDRexp (mg/day)
day) day) day)
High End 184 2.3 1.6 1
Central Tendency 61 1 0.53 0.21
High End 37 0 0.32 0.16
Central Tendency 12 0 0.11 0
High End 18 0 0.16 0
Central Tendency 6 0 5.3E-02 2.1E-02
High End 9 0 0 4.0E-02
Central Tendency 3 0 2.6E-02 1.0E-02

or Dermal Exposures
Benchmark MOE Exposure Estimates: Worker MOE
Exposure Level (= Total UF) No Gloves PF = 5 PF = 10 PF = 20
High End 10 0.00 0.01 0.02 4.5E-02
Central Tendency 10 0.01 0.03 0.07 0.14
High End 100 1.78 8.90 17.79 35.6
Central Tendency 100 5.34 26.69 53.37 106.7
High End 10 12.15 60.75 121.50 243.0
Central Tendency 10 36.45 182.25 364.51 729.0
High End 30 1.19 5.94 11.89 23.8
Central Tendency 30 3.57 17.83 35.67 71.3
High End 10 5.01 25.03 50.05 100.1
Central Tendency 10 15.02 75.08 150.15 300.3
High End 10 0.01 0.05 0.10 0.19
Central Tendency 10 0.03 0.14 0.29 0.57
High End 300 4.12 20.59 41.18 82.4
Central Tendency 300 12.35 61.77 123.54 247.1
High End 10 4.62 23.12 46.25 92.5
Central Tendency 10 13.87 69.37 138.75 277.5
High End 30 0.03 0.15 0.30 0.61
Central Tendency 30 0.09 0.46 0.91 1.82
High End 100 1.58 7.92 15.84 31.7
Central Tendency 100 4.75 23.76 47.52 95.0
High End 30 0.46 2.31 4.62 9.2
Central Tendency 30 1.39 6.94 13.87 27.7
High End 100 27.88 139.38 278.76 557.5
Central Tendency 100 83.63 418.14 836.28 1,672.6
High End 10 0.00 0.02 0.03 6.6E-02
 Central Tendency 10 0.01 0.05 0.10 0.20
High End 300 2.60 12.99 25.98 52.0
Central Tendency 300 7.79 38.96 77.93 155.9
High End 10 17.74 88.70 177.39 354.8
Central Tendency 10 53.22 266.09 532.18 1,064.4
High End 10-4 0.04 0.01 0.00 1.9E-03
Central Tendency 10-4 0.01 0.00 0.00 4.9E-04

Dermal Cancer Risk Estimates

1E-7 1E-6 1E-5 1E-4 1E-3 1E-2 1E-1 1E+0
1
s
, PF = 20) 0.1

0.01

, PF = 10) 0.001 High End

Central Tendency
0.0001
es (PF = 5)
0.00001

es (PF = 1) 0.000001

0.0000001
0.0000001 0.000001 0.00001 0.0001 0.001 0.01 0.1 1
Excess Cancer Risk

High End Central Tendency

3.76E-02 9.70E-03
7.51E-03 1.94E-03
3.76E-03 9.70E-04

1.88E-03 4.85E-04
 Note: This tabl
Key
= Risk. MOEacute or chronic < MOEbenchmark
Cancer Risk > Benchmark Cancer Risk Level

= No Risk. MOEacute or chronic ≥ MOEbenchmark

Cancer Risk ≤ Benchmark Cancer Risk Level

Risk Type Toxicity Endpoint Study

Congenital heart Johnson et al., 2003

malformations
Developmental Developmental Fredriksson et al.,
Toxicity Neurotoxicity 1993
Acute, Non-
Cancer Pre- and Postnatal Narotsky et al., 1995
Mortality

Immunotoxicity Response to infection Selgrade et al., 2010

Increased liver weight,
Liver cytotoxicity, and Kjellstrand et al. 1983
hypertrophy
Kidney Kidney pathology Maltoni, 1986 (Oral)

CNS depression Arito et al., 1994

Neurotoxicity
Trigeminal nerve effects Ruijten et al., 1991

Autoimmunity Keil et al., 2009

Immunotoxicity
Chronic, Immunosuppression Sanders et al., 1982
Non-Cancer
Male Reproductive Toxicity Chia et al. 1996
Reproductive
Toxicity
 Chronic,
Non-Cancer

Reproductive
Toxicity Female Reproductive Narotsky et al., 1995
Toxicity
Congenital Defects Johnson et al., 2003

Developmental Developmental Fredriksson et al.,

Toxicity Neurotoxicity 1993
Pre- and Postnatal Narotsky et al., 1995
Mortality

Chronic, Charbotel et al., 2006

Cancer Kidney, liver, NHL
Cancer (adjusted)

1E-7

APF = 10,000

APF = 1,000

APF = 50

APF = 25

APF = 10

No Respirator

=
 Note: This table only uses monitoring data that is below the
Condition of Use Inhalation Exposure
Select the Condition of Use Data Type HEC Level Exposure Type
(select)

Manufacturing Monitoring Data 99% Worker

8-hr and 12-hr TWA Exposures

Exposure Outputs
Full-Shift (Eight-Hour) Chronic, Non-
Acute Exposures
TWA Exposure Cancer Exposures
Category Exposure Level
ACTCE, 24-hr TWA
CTCE, 8 or 12-hr TWA (ppm) ADCTCE, 24-hr TWA (ppm)
(ppm)
Worker 3 1 1
High End
ONU
Worker 0 0 0
Central Tendency
ONU

Risk Estimation for Inhalation Exposures

Benchmark MOE Exposure Esti
HEC (ppm) Exposure Level (= Total UF) No Respirator APF = 10
High End 10 0.00 0.04
0.0037
Central Tendancy 10 0.03 0.30
High End 100 3.48 34.77
3
Central Tendancy 100 23.99 239.88
High End 10 26.66 266.59
23
Central Tendancy 10 183.91 1839.11
High End 30 2.02 20.17
1.74
Central Tendancy 30 13.91 139.13
High End 10 15.40 154.00
9.1
Central Tendancy 10 106.24 1062.37
High End 10 0.04 0.42
0.025
Central Tendancy 10 0.29 2.92
High End 300 8.12 81.23
4.8
Central Tendancy 300 56.04 560.37
High End 10 8.97 89.69
5.3
Central Tendancy 10 61.87 618.74
High End 30 0.06 0.56
0.033
Central Tendancy 30 0.39 3.85
High End 100 2.88 28.77
1.7
Central Tendancy 100 19.85 198.46
High End 30 0.85 8.46
0.5
Central Tendancy 30 5.84 58.37
 High End 100 62.61 626.15
37
Central Tendancy 100 431.95 4,319.5
High End 10 0.01 0.06
0.0037
Central Tendancy 10 0.04 0.43
High End 300 5.08 50.77
3
Central Tendancy 300 35.02 350.2
High End 10 38.92 389.23
23
Central Tendancy 10 268.51 2685.10
High End 10-4 0.0067 6.7E-04
0.022
Central Tendency 10 -4
0.0007 7.5E-05

Inhalation Cancer Risk Estimates

1E-7 1E-6 1E-5 1E-4 1E-3 1E-2 1E-1 1E+0
1
APF = 10,000
0.1
APF = 1,000
0.01

APF = 50 0.001High End

Central T
APF = 25 0.0001

0.00001
APF = 10
0.000001
No Respirator
0.0000001

Excess Cancer Risk

Inhalation Cancer Risk High End Central Tendency

Estimates
No Respirator 6.67E-03 7.49E-04
APF = 10 6.67E-04 7.49E-05
APF = 25 2.67E-04 3.00E-05

APF = 50 1.33E-04 1.50E-05

APF = 1,000 6.67E-06 7.49E-07
APF = 10,000 6.67E-07 7.49E-08
t is below the OSHA PEL and only shows values that vary from the RR
Dermal
Worker Type

Average Adult Worker

Dermal
Exposure Outputs
Chronic, Cancer
Exposures
Category
LADCTCE, 24-hr TWA
(ppm)
0
Worker, No Gloves
0 Worker with Gloves; PF =
5
Worker with Gloves; PF =
10
Worker with Gloves; PF =
20

Risk Estimation for Dermal Exposures

Exposure Estimates: Worker MOE
HED (mg/kg)
APF = 25 APF = 50 APF = 1,000 APF = 10,000
0.11 0.21 4.29 42.9
0.0052
0.74 1.48 29.59 295.9
86.9 173.9 3,477.3 34,773.2
4.1
599.71 1199.42 23988.41 239,884.1
666.5 1,333.0 26,659.4 266,594.2
28
4597.78 9195.56 183911.11 1,839,111.1
50.4 100.8 2,016.8 20,168.4
2.74
347.83 695.66 13913.28 139,132.8
385.0 770.0 15,399.9 153,998.7
7.9
2655.92 5311.83 106236.65 1,062,366.5
1.1 2.1 42.3 423.1
0.015
7.30 14.59 291.86 2,918.6
203.1 406.2 8,123.0 81,230.1
6.5
1400.92 2801.85 56036.92 560,369.2
224.2 448.5 8,969.2 89,691.6
7.3
1546.85 3093.70 61874.09 618,740.9
1.4 2.8 55.8 558.5
0.048
9.63 19.26 385.25 3,852.5
71.9 143.8 2,876.9 28,769.0
2.5
496.16 992.32 19846.41 198,464.1
21.2 42.3 846.1 8,461.5
0.73
145.93 291.86 5837.18 58,371.8
 1565.37 3130.74 62614.87 626,148.7
44
10798.78 21597.56 431951.22 4,319,512.2
0.16 0.31 6.26 62.6
0.0052
1.08 2.16 43.20 432.0
126.9 253.8 5,076.9 50,768.8
4.1
875.58 1751.15 35023.07 350,230.7
973.1 1,946.1 38,922.8 389,227.6
28
6712.76 13425.51 268510.22 2,685,102.2
0.00 0.00 0.00 6.7E-07
0.0464
0.00 0.00 0.00 7.5E-08

1E-1 1E+0 1E-7 1E-6

1
Protective Gloves
0.1 (Industrial uses, PF = 20)
0.01
Protective Gloves
0.001High End (Commercial uses, PF = 10)
Central Tendency
0.0001
Protective Gloves (PF = 5)
0.00001

0.000001
No Gloves (PF = 1)
0.0000001

0.0000001 0.000001 0.0

Dermal Cancer Risk

Estimates
No Gloves (PF = 1)
Protective Gloves (PF = 5)
Protective Gloves
(Commercial uses, PF = 10)
Protective Gloves
(Industrial uses, PF = 20)
vary from the RR tab.
Dermal
HED Level

99%

Acute Potential Dose Acute Retained Chronic Retained Chronic Retained

Rate Dose Dose, Non-Cancer Dose, Cancer
Exposure Level
ARDTCE (mg/kg- CRD (mg/kg-day) CRD (mg/kg-day)
APDRexp (mg/day)
day) TCE TCE

High End 184 2.3 1.6 1

Central Tendency 61 1 0.53 0.21
High End 37 0 0.32 0.16
Central Tendency 12 0 0.11 0
High End 18 0 0.16 0
Central Tendency 6 0 5.3E-02 2.1E-02
High End 9 0 0 4.0E-02
Central Tendency 3 0 2.6E-02 1.0E-02

or Dermal Exposures
Benchmark MOE Exposure Estimates: Worker MOE
Exposure Level (= Total UF) No Gloves PF = 5 PF = 10 PF = 20
High End 10 0.00 0.01 0.02 4.5E-02
Central Tendency 10 0.01 0.03 0.07 0.14
High End 100 1.78 8.90 17.79 35.6
Central Tendency 100 5.34 26.69 53.37 106.7
High End 10 12.15 60.75 121.50 243.0
Central Tendency 10 36.45 182.25 364.51 729.0
High End 30 1.19 5.94 11.89 23.8
Central Tendency 30 3.57 17.83 35.67 71.3
High End 10 5.01 25.03 50.05 100.1
Central Tendency 10 15.02 75.08 150.15 300.3
High End 10 0.01 0.05 0.10 0.19
Central Tendency 10 0.03 0.14 0.29 0.57
High End 300 4.12 20.59 41.18 82.4
Central Tendency 300 12.35 61.77 123.54 247.1
High End 10 4.62 23.12 46.25 92.5
Central Tendency 10 13.87 69.37 138.75 277.5
High End 30 0.03 0.15 0.30 0.61
Central Tendency 30 0.09 0.46 0.91 1.82
High End 100 1.58 7.92 15.84 31.7
Central Tendency 100 4.75 23.76 47.52 95.0
High End 30 0.46 2.31 4.62 9.2
Central Tendency 30 1.39 6.94 13.87 27.7
 High End 100 27.88 139.38 278.76 557.5
Central Tendency 100 83.63 418.14 836.28 1,672.6
High End 10 0.00 0.02 0.03 6.6E-02
Central Tendency 10 0.01 0.05 0.10 0.20
High End 300 2.60 12.99 25.98 52.0
Central Tendency 300 7.79 38.96 77.93 155.9
High End 10 17.74 88.70 177.39 354.8
Central Tendency 10 53.22 266.09 532.18 1,064.4
High End 10-4 0.04 0.01 0.00 1.9E-03
Central Tendency 10 -4
0.01 0.00 0.00 4.9E-04

Dermal Cancer Risk Estimates

1E-7 1E-6 1E-5 1E-4 1E-3 1E-2 1E-1 1E+0
1
es
s, PF = 20) 0.1

0.01

s, PF = 10) 0.001 High End

Central Tendency
0.0001
es (PF = 5)
0.00001

es (PF = 1) 0.000001

0.0000001
0.0000001 0.000001 0.00001 0.0001 0.001 0.01 0.1 1
Excess Cancer Risk

High End Central Tendency

3.76E-02 9.70E-03
7.51E-03 1.94E-03
3.76E-03 9.70E-04

1.88E-03 4.85E-04
Look-up Values and Risk Parameter Values
All values are adjusted to match 24hr exposure

Toxicity Endpoint
Congenital heart malformations
Developmental Toxicity Developmental Neurotoxicity
Acute, Non-Cancer Pre- and Postnatal Mortality
Immunotoxicity
Response to infection
Increased liver weight, cytotoxicity, and
Liver hypertrophy
Kidney Kidney pathology
CNS depression
Neurotoxicity
Trigeminal nerve effects
Autoimmunity
Chronic, Non-Cancer Immunotoxicity
Immunosuppression
Reproductive Male Reproductive Toxicity
Toxicity Female Reproductive Toxicity
Congenital Defects
Developmental Toxicity Developmental Neurotoxicity
Pre- and Postnatal Mortality

Chronic, Cancer Cancer Kidney, liver, NHL

 Inhalation Dermal
Acute and Chronic, Non-Cancer Parameters

HEC99 HED50 HED99

Study Code HEC50 (ppm) (ppm) (mg/kg) (mg/kg) Benchmark MOE
Johnson et al., 2003 Tox1 0.012 0.0037 0.0058 0.0052 10
Fredriksson et al., 1993 Tox2 8 3 4.2 4.1 100
Narotsky et al., 1995 Tox3 57 23 29 28 10
Tox4 N/A 1.74 N/A 2.74 30
Selgrade et al., 2010
Tox5 25 9.1 9.0 7.9 10
Kjellstrand et al. 1983
Maltoni, 1986 (Oral) Tox6 0.19 0.025 0.15 0.015 10
Arito et al., 1994 Tox7 13 4.8 6.6 6.5 300
Ruijten et al., 1991 Tox8 14 5.3 7.4 7.3 10
Keil et al., 2009 Tox9 0.092 0.033 0.049 0.048 30
Sanders et al., 1982 Tox10 4.8 1.7 2.5 2.5 100
Chia et al. 1996 Tox11 1.4 0.5 0.74 0.73 30
Narotsky et al., 1995 Tox12 98 37 47 44 100
Johnson et al., 2003 Tox13 0.012 0.0037 0.0058 0.0052 10
Fredriksson et al., 1993 Tox14 8 3 4.2 4.1 300
Narotsky et al., 1995 Tox15 57 23 29 28 10
Charbotel et al., 2006 Tox16 -- -- -- -- --
(adjusted)
Inhalation Dermal
Cancer Parameters Look-up Table Values

OSP (mg/kg-
IUR (ppm )-1 1
) HEC/HED Percentiles Exposure Percentiles
-- -- HEC99 High End
-- -- HEC50 Central Tendancy
-- -- HED99
-- -- (Selgrade POD is not
PBPK modeled) HED50
-- --

-- --
-- --
-- --
-- -- HEC conversion factor
-- -- 0.186
-- -- TCE MW 131.39
-- -- Molar Volume 24.45
-- --
-- --
-- --

0.022 0.0464
Table Values

Target Cancer Risk Level

1.0E-06
1.0E-05
1.0E-04

ppm/mg/m3
g/mol
L/mol
 Max
Look-up Name Condition of Use Bin Yderm
Manufacturing Manufacturing 1 1
Processing as a Reactant Processing as a Reactant 1 1
Industrial Processing Aid (12-hr) Industrial Processing Aid 1 1
Formulation of Aerosol and Non- Formulation of Aerosol and Non-Aerosol
Aerosol Products Products 1 1
Repackaging Repackaging 1 1
Process Solvent Recycling and Worker Process Solvent Recycling and Worker
Handling of Wastes Handling of Wastes 1 1
Other Industrial Uses Other Industrial Uses 1 1
Batch Open Top Vapor Degreasing Batch Open Top Vapor Degreasing
2 1
Batch Open Top Vapor Degreasing Batch Open Top Vapor Degreasing (12-hr)
(12-hr) 2 1
Batch Closed-Loop Vapor Degreasing Batch Closed-Loop Vapor Degreasing
Systems Systems 2 1
Conveyorized Vapor Degreasing Conveyorized Vapor Degreasing 2 1
Web Vapor Degreasing Web Vapor Degreasing 2 1
Cold Cleaning Cold Cleaning 2 1

Aerosol Applications: Spray Aerosol Applications: Spray

Degreasing/Cleaning, Automotive Degreasing/Cleaning, Automotive Brake
Brake and Parts Cleaners, Penetrating and Parts Cleaners, Penetrating Lubricants,
Lubricants, and Mold Releases and Mold Releases
3 1
Adhesives, Sealants, Paints, and Adhesives, Sealants, Paints, and Coatings
Coatings (Industrial) (Industrial) 3 0.9
Adhesives, Sealants, Paints, and Adhesives, Sealants, Paints, and Coatings
Coatings (Commercial) (Commercial) 3 0.9
Spot Cleaning, Wipe Cleaning and Spot Cleaning, Wipe Cleaning and Carpet
Carpet Cleaning (12-hr) Cleaning (12-hr) 4 1
Spot Cleaning, Wipe Cleaning and Spot Cleaning
Carpet Cleaning 4 1
Spot Cleaning, Wipe Cleaning and Wipe Cleaning
Carpet Cleaning 4 1
Spot Cleaning, Wipe Cleaning and Carpet Cleaning
Carpet Cleaning 4 1
Other Commercial Uses Other Commercial Uses 4 1
Metalworking Fluids Metalworking Fluids 4 0.8
Commercial Printing and Copying Commercial Printing and Copying 4 0.35
 Occlusion Fraction Absorbed, Occluded Fraction
Considered? fabs Absorbed
No 0.08 N/A
No 0.08 N/A
No 0.08 N/A

No 0.08 N/A
No 0.08 N/A

No 0.08 N/A
No 0.08 N/A

Yes 0.08 1

Yes 0.08 1

Yes 0.08 1
Yes 0.08 1
Yes 0.08 1
Yes 0.08 1

No 0.13 N/A

No 0.08 N/A

No 0.13 N/A

Yes 0.13 1

Yes 0.13 1

Yes 0.13 1

Yes 0.13 1
Yes 0.13 1
Yes 0.08 1
Yes 0.13 1
 For Dashboard

Look-up Name Condition of Use Worker Type

Average Adult
Manufacturing Manufacturing Worker
Average Adult
Manufacturing Manufacturing Worker
For Risk Reduction (RR) Heat Map
Average Adult
Manufacturing Manufacturing Worker
Average Adult
Manufacturing Manufacturing Worker
 Dermal Calculation Num

Fraction Exposure Frequency

Exposure Category Exposure Max Yderm Calculated (EF)
Level Absorbed, Fabs
Bin (days/yr)

No Gloves High End 1 1.00 0.08 250

Central
No Gloves 1 1.00 0.08 250
Tendency
Map
No Gloves High End 1 1.00 0.08 250

Central
No Gloves 1 1.00 0.08 250
Tendency
Dermal Calculation Numbers
Exposure Frequency 2-Hand Surface Body Weight Quantity Remaining on Skin Acute Potential Dose Rate
(FT) (Qu)
Area (cm2) (kg)
(event/day) (mg/cm2-event) APDRexp (mg/day)

1 1,070 80 2.1 184.36

1 535 80 1.4 61.45

1 1,070 80 2.1 184.36

1 535 80 1.4 61.45

 Calculated Doses
Chronic Retained Dose, Non- Chronic Retained Dose, Cancer
Acute Retained Dose Cancer
ARDTCE (mg/kg-day) CRDTCE (mg/kg-day) CRDTCE (mg/kg-day)

2.30 1.58 0.81

0.77 0.53 0.21

2.30 1.58 0.81

0.77 0.53 0.21

 Exposure
OES Group Condition of Use Category Scenario
15, 18 Adhesives, Sealants, Paints, and Coatings (Commercial) ONU 8-hr
15, 18 Adhesives, Sealants, Paints, and Coatings (Commercial) Worker 8-hr

15, 18 Adhesives, Sealants, Paints, and Coatings (Industrial) ONU 8-hr

15, 18 Adhesives, Sealants, Paints, and Coatings (Industrial) Worker 8-hr

9c-e Batch Closed-Loop Vapor Degreasing Systems ONU 8-hr

9c-e Batch Closed-Loop Vapor Degreasing Systems Worker 8-hr
9a-b Batch Open Top Vapor Degreasing ONU 8-hr

9a-b Batch Open Top Vapor Degreasing Worker 8-hr

9a-b Batch Open Top Vapor Degreasing (12-hr) Worker 12-hr

24 Commercial Printing and Copying ONU 8-hr

24 Commercial Printing and Copying Worker 8-hr

9f-g Conveyorized Vapor Degreasing ONU 8-hr

9f-g Conveyorized Vapor Degreasing Worker 8-hr

4 Formulation of Aerosol and Non-Aerosol Products Worker 8-hr

22, 23a-b Industrial Processing Aid (12-hr) ONU 12-hr

22, 23a-b Industrial Processing Aid (12-hr) Worker 12-hr
1 Manufacturing ONU 8-hr
1 Manufacturing Worker 8-hr
13 Metalworking Fluids ONU 8-hr
13 Metalworking Fluids Worker 8-hr
22, 23, 24 Other Industrial Uses Worker 8-hr
7 & 28 Process Solvent Recycling and Worker Handling of Wastes Worker 8-hr
3 Processing as a Reactant Worker 8-hr
6 Repackaging ONU 8-hr
6 Repackaging Worker 8-hr
19-21, 26 Spot Cleaning, Wipe Cleaning and Carpet Cleaning ONU 8-hr
19-21, 26 Spot Cleaning, Wipe Cleaning and Carpet Cleaning Worker 8-hr
19-21, 26 Spot Cleaning, Wipe Cleaning and Carpet Cleaning (12-hr) Worker 12-hr
19-21, 26 Other Commercial Uses Worker 8-hr
19-21, 26 Other Commercial Uses ONU 8-hr
19-21, 26 Other Commercial Uses Worker 8-hr
Aerosol Applications: Spray Degreasing/Cleaning, Automotive
11, 12, 14, 16, 25 Brake and Parts Cleaners, Penetrating Lubricants, and Mold ONU 8-hr
Releases
Aerosol Applications: Spray Degreasing/Cleaning, Automotive
11, 12, 14, 16, 25 Brake and Parts Cleaners, Penetrating Lubricants, and Mold Worker 8-hr
Releases
 9a-b Batch Open Top Vapor Degreasing ONU 8-hr
9a-b Batch Open Top Vapor Degreasing Worker 8-hr
10 Cold Cleaning ONU 8-hr
10 Cold Cleaning Worker 8-hr
9f-g Conveyorized Vapor Degreasing ONU 8-hr
9f-g Conveyorized Vapor Degreasing Worker 8-hr

13 Metalworking Fluids Worker 8-hr

19-21, 26 Spot Cleaning, Wipe Cleaning and Carpet Cleaning ONU 8-hr
19-21, 26 Spot Cleaning, Wipe Cleaning and Carpet Cleaning Worker 8-hr
9h Web Vapor Degreasing ONU 8-hr

9h Web Vapor Degreasing Worker 8-hr

Exposure Eight Hour TWA
Frequency Acute Exposures
Exposures
CTCE, 8 or 12- ACTCE, 24-hr TWA
(days/yr)
hrTWA (ppm) (ppm)
Central
High End 95th Percentile 50th Percentile 95th Percentile 50th Percentile
Tendency
250 250 1.00 0.94 0.33 0.31
250 250 39.49 4.64 13.16 1.55

250 250 1.00 0.94 0.33 0.31

250 250 39.49 4.64 13.16 1.55

250 250 -- -- -- --
250 250 1.45 0.46 0.48 0.15
250 250 9.09 1.11 3.03 0.37

250 250 77.76 13.80 25.92 4.60

250 250 4.19 4.19 2.10 2.10

250 250 -- -- -- --

250 250 2.10 0.09 0.70 0.03

250 250 -- -- -- --
250 250 48.29 32.38 16.10 10.79

250 250 1.14 0.00 0.38 0.00

250 250 2.90 1.31 1.45 0.66

250 250 12.81 4.25 6.40 2.13
250 250 -- -- -- --
250 250 2.59 0.38 0.86 0.13
250 250 -- -- -- --
250 250 75.38 69.69 25.13 23.23
250 250 2.59 0.38 0.86 0.13
250 250 1.14 0.00 0.38 0.00
250 250 2.59 0.38 0.86 0.13
250 250 -- -- -- --
250 250 1.14 0.00 0.38 0.00
293 258 -- -- -- --
293 258 3 0.38 0.95 0.13
293 258 0.94 0.94 0.47 0.47
293 258 3 0.38 0.95 0.13
293 258 1.75 0.48 0.58 0.16
293 258 2.77 0.96 0.92 0.32

250 250 1.04 0.14 0.35 0.05

250 250 23.98 7.63 7.99 2.54

250 250 237 18.10 79.00 6.03
250 250 388 34.80 129.33 11.60
250 250 34.70 1.84 11.57 0.61
250 250 57.20 3.330 19.07 1.11
250 250 1878 23 626.00 7.77
250 250 3043.00 40.80 1014.33 13.60

250 250 0.26 0.07 0.09 0.02

293 258 1.75 0.48 0.58 0.16

293 258 2.77 0.96 0.92 0.32
250 250 9.57 3.13 3.19 1.04

250 250 14.14 5.944 4.71 1.98

Chronic, Non- Chronic, Cancer
Cancer
ADCTCE,Exposures
24-hr Exposures
LADCTCE, 24-hr
TWA (ppm) TWA (ppm)
95th Percentile 50th Percentile 95th Percentile 50th Percentile Data Points
0.23 0.21 0.12 0.09 2
9.02 1.06 4.62 0.42 22

0.23 0.21 0.12 0.09 2

9.02 1.06 4.62 0.42 22

-- -- -- -- 0
0.33 0.10 0.17 0.04 19
2.08 0.25 1.06 0.10 10

17.75 3.15 9.10 1.25 113

1.43 1.43 0.74 0.57 1

-- -- -- -- 0

0.48 0.02 0.25 0.01 20

-- -- -- -- 0
11.02 7.39 5.65 2.94 18

0.26 0.00 0.13 0.00 33

0.99 0.45 0.51 0.18 4

4.39 1.46 2.25 0.58 30
-- -- -- -- 0
0.59 0.09 0.30 0.03 16
-- -- -- -- 0
17.21 15.91 8.83 6.32 3
0.59 0.09 0.30 0.03 16
0.26 0.00 0.13 0.00 33
0.59 0.09 0.30 0.03 16
-- -- -- -- 0
0.26 0.00 0.13 0.00 33
-- -- -- -- 0
0.67 0.09 0.3 0.04 8
0.33 0.33 0.17 0.13 1
0.67 0.09 0.3 0.04 8
0.41 0.11 0.16 0.04 N/A
0.65 0.23 0.26 0.08 N/A

0.24 0.03 0.09 0.01 N/A

5.48 1.74 2.21 0.65 N/A

 54.0 4.14 21.1 1.54 N/A
88.5 8.0 35.3 2.96 N/A
7.9 0.42 3.13 0.15 N/A
13.10 0.76 5.15 0.28 N/A
429 5.33 168 3.61 N/A
694.80 9.32 275.20 5.33 N/A

0.06 0.02 0.03 0.01 N/A

0.41 0.11 0.16 0.04 N/A

0.65 0.23 0.26 0.08 N/A
2.18 0.71 0.87 0.27 N/A

3.23 1.36 1.32 0.51 N/A

 Sources & Notes Data Type
Monitoring Data
Monitoring Data
Added 5/15 - industrial data used as Monitoring Data
surrogate for commercial.
Added 5/15 - industrial data used as
surrogate for commercial. Monitoring Data

Monitoring Data
Monitoring Data
Used all degreasing data not marked as
Monitoring Data
closed
Used all degreasing data not marked as
closed Monitoring Data

Used all degreasing data not marked as Monitoring Data

closed
Monitoring Data

Monitoring Data

Added 5/8 Monitoring Data

Added 5/8 Monitoring Data

Uses Repackaging data as a surrogate. Monitoring Data

Added 5/8 Monitoring Data

Added 5/8 Monitoring Data
Monitoring Data
HSIA Data for Mfg Monitoring Data
Monitoring Data
Monitoring Data
Uses HSIA data for Mfg as surrogate Monitoring Data
Uses Repackaging data as a surrogate. Monitoring Data
Uses HSIA data for Mfg as surrogate Monitoring Data
Monitoring Data
Monitoring Data
Monitoring Data
Monitoring Data
Monitoring Data
Uses spot cleaning data as surrogate. Monitoring Data
NF/FF Model (10.16.2018 model run), using spo
Modeled Data
NF/FF Model (10.16.2018 model run), using spoModeled Data

NF/FF Model (8.19.2018 model run) Modeled Data

NF/FF Model (8.19.2018 model run) Modeled Data

NF/FF Model (10.04.2018 model run) Modeled Data
NF/FF Model (10.04.2018 model run) Modeled Data
NF/FF Model (10.04.2018 model run) Modeled Data
NF/FF Model (10.04.2018 model run) Modeled Data
NF/FF Model (10.04.2018 model run) Modeled Data
NF/FF Model (10.04.2018 model run) Modeled Data
2011 ESD on Use of Metalworking Fluids -
May underestimate exposure as value ony Modeled Data
includes mist portion, additional exposure
may occur to volatilized TCE
NF/FF Model (10.16.2018 model run) Modeled Data
NF/FF Model (10.16.2018 model run) Modeled Data
Web Degreasing Model (4.30.2019) - Added
Modeled Data
5/2/19
Web Degreasing Model (4.30.2019) - Added Modeled Data
5/2/19
 Note: This table only uses moni
Exposure Frequency (days/yr)

Exposure High End

OES Group Condition of Use Category Scenario

Adhesives, Sealants, Paints, and Coatings (Commercial) ONU 8-hr 250

15, 18
Adhesives, Sealants, Paints, and Coatings (Commercial) Worker 8-hr 250
15, 18
Adhesives, Sealants, Paints, and Coatings (Industrial) ONU 8-hr 250
15, 18
Adhesives, Sealants, Paints, and Coatings (Industrial) Worker 8-hr 250
15, 18
9c-e Batch Closed-Loop Vapor Degreasing Systems ONU 8-hr 250
9c-e Batch Closed-Loop Vapor Degreasing Systems Worker 8-hr 250
9a-b Batch Open Top Vapor Degreasing ONU 8-hr 250
9a-b Batch Open Top Vapor Degreasing Worker 8-hr 250
9a-b Batch Open Top Vapor Degreasing (12-hr) Worker 12-hr 250
24 Commercial Printing and Copying ONU 8-hr 250
24 Commercial Printing and Copying Worker 8-hr 250
9f-g Conveyorized Vapor Degreasing ONU 8-hr 250
9f-g Conveyorized Vapor Degreasing Worker 8-hr 250
4 Formulation of Aerosol and Non-Aerosol Products Worker 8-hr 250
22, 23a-b Industrial Processing Aid (12-hr) ONU 12-hr 250
22, 23a-b Industrial Processing Aid (12-hr) Worker 12-hr 250
1 Manufacturing ONU 8-hr 250
1 Manufacturing Worker 8-hr 250
13 Metalworking Fluids ONU 8-hr 250
13 Metalworking Fluids Worker 8-hr 250
22, 23, 24 Other Industrial Uses Worker 8-hr 250

Worker 8-hr 250

7 & 28 Process Solvent Recycling and Worker Handling of Wastes
3 Processing as a Reactant Worker 8-hr 250
6 Repackaging ONU 8-hr 250
6 Repackaging Worker 8-hr 250
19-21, 26 Spot Cleaning, Wipe Cleaning and Carpet Cleaning ONU 8-hr 293
19-21, 26 Spot Cleaning, Wipe Cleaning and Carpet Cleaning Worker 8-hr 293

Worker 12-hr 293

19-21, 26 Spot Cleaning, Wipe Cleaning and Carpet Cleaning (12-hr)
19-21, 26 Other Commercial Uses Worker 8-hr 293
19-21, 26 Other Commercial Uses ONU 8-hr 293
19-21, 26 Other Commercial Uses Worker 8-hr 293
11, 12, 14, Aerosol Degreasing and Aerosol Lubricants ONU 8-hr 250
16, 25
11, 12, 14, Aerosol Degreasing and Aerosol Lubricants Worker 8-hr 250
16, 25
9a-b Batch Open Top Vapor Degreasing ONU 8-hr 250
9a-b Batch Open Top Vapor Degreasing Worker 8-hr 250
10 Cold Cleaning ONU 8-hr 250
10 Cold Cleaning Worker 8-hr 250
9f-g Conveyorized Vapor Degreasing ONU 8-hr 250
9f-g Conveyorized Vapor Degreasing Worker 8-hr 250

Worker 8-hr 250

13 Metalworking Fluids
19-21, 26 Spot Cleaning, Wipe Cleaning and Carpet Cleaning ONU 8-hr 293
19-21, 26 Spot Cleaning, Wipe Cleaning and Carpet Cleaning Worker 8-hr 293
9h Web Vapor Degreasing ONU 8-hr 250
9h Web Vapor Degreasing Worker 8-hr 250
e only uses monitoring data that is below the OSHA PEL and only sh
Eight Hour TWA Exposures Acute Exposures Chronic, Non-Cancer Exposures
xposure Frequency (days/yr)
CTCE, 8 or 12-hrTWA (ppm) ACTCE, 24-hr TWA (ppm) ADCTCE, 24-hr TWA (ppm)
Central 95th Percentile 50th Percentile 95th Percentile 50th Percentile 95th Percentile 50th Percentile
Tendency

250 1.00 0.94 0.33 0.31 0.23 0.21

250 39.49 4.64 13.16 1.55 9.02 1.06

250 1.00 0.94 0.33 0.31 0.23 0.21

250 39.49 4.64 13.16 1.55 9.02 1.06

250 -- -- -- -- -- --
250 1.45 0.46 0.48 0.15 0.33 0.10
250 9.09 1.11 3.03 0.37 2.08 0.25
250 57.69 12.78 19.23 4.26 13.17 2.92
250 1.43 1.43 0.72 0.72 0.49 0.49
250 -- -- -- -- -- --
250 2.10 0.09 0.70 0.03 0.48 0.02
250 -- -- -- -- -- --
250 48.29 32.38 16.10 10.79 11.02 7.39
250 12.81 4.25 4.27 1.42 2.92 0.97
250 2.90 1.31 1.45 0.66 0.99 0.45
250 12.81 4.25 6.40 2.13 4.39 1.46
250 -- -- -- -- -- --
250 2.59 0.38 0.86 0.13 0.59 0.09
250 -- -- -- -- -- --
250 75.38 69.69 25.13 23.23 17.21 15.91
250 2.59 0.38 0.86 0.13 0.59 0.09

250 1.14 0.00 0.38 0.00 0.26 0.00

250 2.59 0.38 0.86 0.13 0.59 0.09

250 -- -- -- -- -- --
250 1.14 0.00 0.38 0.00 0.26 0.00
258 -- -- -- -- -- --
258 2.85 0.38 0.95 0.13 0.67 0.09

258 0.94 0.94 0.47 0.47 0.33 0.33

258 3 0.38 0.95 0.13 0.67 0.09

258 1.75 0.48 0.58 0.16 0.41 0.11
258 2.77 0.96 0.92 0.32 0.65 0.23

250 1.04 0.14 0.35 0.05 0.24 0.03

250 23.98 7.63 7.99 2.54 5.48 1.74

250 237.00 18.10 79.00 6.03 54.00 4.14

250 388.00 34.80 129.33 11.60 88.50 7.96
250 34.70 1.84 11.57 0.61 7.90 0.42
250 57.20 3.33 19.07 1.11 29.10 0.76
250 1878.00 23.30 626.00 7.77 428.80 5.33
250 3043.00 40.80 1014.33 13.60 694.80 9.32

250 0.26 0.07 0.09 0.02 0.06 0.02

258 1.75 0.48 0.58 0.16 0.41 0.13

258 2.77 0.96 0.92 0.32 0.65 0.23
250 9.57 3.13 3.19 1.04 2.18 0.73
250 14.30 5.94 4.77 1.98 3.23 1.36
and only shows values for CoUs affected.
Chronic, Cancer Exposures
LADCTCE, 24-hr TWA (ppm)

95th Percentile 50th Percentile Data Points Sources & Notes

0.12 0.09 2
Added 5/15 - industrial data used as surrogate for commercial.
4.62 0.42 22
Added 5/15 - industrial data used as surrogate for commercial.
0.12 0.09 2

4.62 0.42 22

-- -- 0
0.17 0.04 19
1.06 0.10 10 Used all degreasing data not marked as closed
6.75 1.16 108 Used all degreasing data not marked as closed
0.25 0.20 1 Used all degreasing data not marked as closed
-- -- 0
0.25 0.01 20
-- -- 0 Added 5/8
5.65 2.94 18 Added 5/8
1.50 0.39 30 Uses Repackaging data as a surrogate.
0.51 0.18 4 Added 5/8
2.25 0.58 30 Added 5/8
-- -- 0
0.30 0.03 16 HSIA Data for Mfg
-- -- 0
8.83 6.32 3
0.30 0.03 16 Uses HSIA data for Mfg as surrogate

0.13 0.00 33
Uses Repackaging data as a surrogate.
0.30 0.03 16 Uses HSIA data for Mfg as surrogate
-- -- 0
0.13 0.00 33
-- -- 0
0.34 0.04 8

0.17 0.13 1

0.3 0.04 8 Uses spot cleaning data as surrogate.

0.16 0.04 N/A NF/FF Model (10.16.2018 model run), using spot cleaning data as surrogate.
0.26 0.08 N/A NF/FF Model (10.16.2018 model run), using spot cleaning data as surrogate.

0.09 0.01 N/A NF/FF Model (8.19.2018 model run)

 2.21 0.65 N/A NF/FF Model (8.19.2018 model run)

21.10 1.54 N/A NF/FF Model (10.04.2018 model run)

35.30 2.96 N/A NF/FF Model (10.04.2018 model run)
3.29 0.15 N/A NF/FF Model (10.04.2018 model run)
5.15 0.28 N/A NF/FF Model (10.04.2018 model run)
168.30 3.61 N/A NF/FF Model (10.04.2018 model run)
275.20 5.33 N/A NF/FF Model (10.04.2018 model run)

2011 ESD on Use of Metalworking Fluids - May underestimate exposure as

0.03 0.01 N/A value ony includes mist portion, additional exposure may occur to
volatilized TCE
0.16 0.04 N/A NF/FF Model (10.16.2018 model run)
0.26 0.08 N/A NF/FF Model (10.16.2018 model run)
0.87 0.27 N/A Web Degreasing Model (4.30.2019) - Added 5/2/19
1.32 0.53 N/A Web Degreasing Model (4.30.2019) - Added 5/2/19
Data Type

Monitoring Data

Monitoring Data

Monitoring Data
Monitoring Data

Monitoring Data
Monitoring Data
Monitoring Data
Monitoring Data
Monitoring Data
Monitoring Data
Monitoring Data
Monitoring Data
Monitoring Data
Monitoring Data
Monitoring Data
Monitoring Data
Monitoring Data
Monitoring Data
Monitoring Data
Monitoring Data
Monitoring Data

Monitoring Data

Monitoring Data
Monitoring Data
Monitoring Data
Monitoring Data
Monitoring Data

Monitoring Data

Monitoring Data
Modeled Data
Modeled Data

Modeled Data
Modeled Data

Modeled Data
Modeled Data
Modeled Data
Modeled Data
Modeled Data
Modeled Data

Modeled Data

Modeled Data
Modeled Data
Modeled Data
Modeled Data
 Conditions of Use
Adhesives, Sealants, Paints, and Coatings (Commercial)
Adhesives, Sealants, Paints, and Coatings (Industrial)
Aerosol Applications: Spray Degreasing/Cleaning, Automotive Brake and Parts Cleaners,
Penetrating Lubricants, and Mold Releases
Batch Closed-Loop Vapor Degreasing Systems
Batch Open Top Vapor Degreasing
Batch Open Top Vapor Degreasing (12-hr)
Cold Cleaning
Commercial Printing and Copying
Conveyorized Vapor Degreasing
Formulation of Aerosol and Non-Aerosol Products
Industrial Processing Aid (12-hr)
Manufacturing
Metalworking Fluids
Other Commercial Uses
Other Industrial Uses
Process Solvent Recycling and Worker Handling of Wastes
Processing as a Reactant
Repackaging
Spot Cleaning, Wipe Cleaning and Carpet Cleaning
Spot Cleaning, Wipe Cleaning and Carpet Cleaning (12-hr)
Web Vapor Degreasing
 Exposure Data Types Assigned Glove Protection Factor
Monitoring Data 5
Modeled Data 10

20
Worker Type
Average Adult Worker Exposure Type
Females of Reproductive Age Worker
ONU
BMDL Percentile
50% Trichloroethylene
99% MW
Molar Volume
Assigned Respirator Protection Factor
10 Parameter Name
25 Exposure Duration (8-hr)
50 Exposure Duration (12-hr)
1000 Acute Exposure Averaging Time
10000 Exposure Frequency
Working Years Per Lifetime (Mid)
Working Years Per Lifetime (High)
Lifetime Years for LADC
Averaging time For ADC (Mid)
Averaging time For ADC (High)
Averaging time For LADC
General uses, PF = 5
Commercial uses, PF = 10

Industrial uses, PF = 20

Value Unit
131.39 g/mol
24.45 L/mol

Symbol Value Unit

ED_8 8 hr/day
ED_12 12 hr/day
AT 24 hr/day
EF 250 day/yr
WY_mid 31 yr
WY_high 40 yr
LT 78 yr
AT_ADC_mid 271,560 hr
AT_ADC_high 350,400 hr
AT_LADC 683,280 hr
Exposure Factors

Average Females of
Reproductive Characterization of
Adult Value
Worker Age
Body Weight, BW (kg) 80 72.4
1 Hand Surface Area (cm )
2
535 445 Central Tendency
2 Hand Surface Area (cm2) 1070 890 High End
Working Years - High-End (yr) 40 40 High End

Working Years - Central Tendency (yr) 31 31 Central Tendency

Lifetime 78 78

Woman of Childbearing Age Exposure Factors:

Body Weight:
From the Exposure Factors Handbook Table 8-5: Mean and Percentile Body Weights (kg) for Females Derived from NHAN
Age 16 to <21 years: 65.9 kg (mean)
Age 21 to <30 years: 71.9 kg (mean)
Age 30 to <40 years: 74.8 kg (mean)
Age 40 to <50 years: 77.1 kg (mean)

(1) U.S. Environmental Protection Agency (EPA). (2011) Exposure Factors Handbook:
2011 Edition. National Center for Environmental Assessment, Washington, DC;
EPA/600/R-09/052F. Available from the National Technical Information Service,
Springfield, VA, and online at http://www.epa.gov/ncea/efh.
for Females Derived from NHANES (1990-2006) (1)